Get started
Author

Maggie S.H. Cheung

Observed names: Cheung, Maggie S. H., Maggie Cheung, Maggie S H Cheung, Maggie S-H. Cheung, Maggie S. H. Cheung
OpenAlex ID: A5110679324
Promoting the Delivery of Nanoparticles to Atherosclerotic Plaques by DNA Coating
2018 · Lei Zhang, Xiao Yu Tian, et al. · ACS Applied Materials & Interfaces · 59
Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?
2020 · Herbert H-F. Loong, Alissa M Wong, et al. · Journal of Clinical Neuroscience · 55
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
2020 · Winnie Yeo, Thomas KH. Lau, et al. · The Breast · 42
PDF
AI-doscopist: a real-time deep-learning-based algorithm for localising polyps in colonoscopy videos with edge computing devices
2020 · Carmen C. Y. Poon, Yuqi Jiang, et al. · npj Digital Medicine · 40
PDF
MRI detection of endothelial cell inflammation using targeted superparamagnetic particles of iron oxide (SPIO)
2017 · Joyce M. S. Chan, Maggie S. H. Cheung, et al. · Clinical and Translational Medicine · 30
PDF
Imaging vulnerable plaques by targeting inflammation in atherosclerosis using fluorescent-labeled dual-ligand microparticles of iron oxide and magnetic resonance imaging
2017 · Joyce M.S. Chan, Claudia Monaco, et al. · Journal of Vascular Surgery · 26
Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
2021 · Winnie Yeo, Frankie K.F. Mo, et al. · The Oncologist · 22
PDF
High-fidelity KKH variant of Staphylococcus aureus Cas9 nucleases with improved base mismatch discrimination
2021 · Chaya T L Yuen, Dawn G L Thean, et al. · Nucleic Acids Research · 21
PDF
Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
2020 · Winnie Yeo, Vicky T.C. Chan, et al. · Data in Brief · 10
PDF
Rapid customization of base editors via machine learning-powered combinatorial mutagenesis
2026 · Jiaxing Peng, Don C.T. Chan, et al. · Molecular Cell · 5
Resources for: Rapid customization of base editors via machine learning-powered combinatorial mutagenesis (MLDE/ProteinMPNN workflow on TadA)
2026 · PENG, Jiaxing, Chan, Chiu Tung, et al. · Zenodo (CERN European Organization for Nuclear Research)
Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
PDF
Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S6 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S4 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S3 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S5 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Data from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S1 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Supplementary Table S2 from A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
2023 · Feng Xu, Man Tong, et al.
Works count: 28
Citation count: 310
H-index: 9
I10-index: 9
Year
Topic
Type